Compare Vipshop Holdings Ltd - ADR (VIPS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vipshop Holdings Ltd - ADR vs Viatris Inc — how do they compare? Vipshop Holdings Ltd - ADR trades at $14.63 (market cap $7.01B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 2.8× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.25%). Which is the better fit depends on your goals.
| VIPS | VTRS | |
|---|---|---|
Market Cap | $7.01B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $20.68 | $17.39 |
52-Week Low | $12.92 | $8.74 |
Enterprise Value | $3.60B | $32.00B |
Dividend Yield | 4.25% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vipshop Holdings (VIPS) trades at $14.69, up 1.31% with a bullish technical signal. The stock shows strong fundamentals with a low P/E of 6.66 and robust profitability metrics including 18.43% ROE. Recent Q1 2026 earnings met expectations with management focusing on outlet strategy expansion through REIT spinoffs to drive growth.
The outlook remains positive with 53.57% analyst buy ratings supporting valuation upside potential. Key risks include Chinese consumer spending volatility and competitive e-commerce pressures. Revenue stabilization and margin improvements in 2026 projections suggest recovery potential after recent declines.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
